Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats

International Journal of Pharmaceutics

Volumn 336, Issue 2, 2007, Pages 233-240

  Jain, Ritesh ^a   Duvvuri, Sridhar ^b   Kansara, Viral ^a   Mandava, Nanda Kishore ^a   Mitra, Ashim K ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b WYETH RESEARCH   (United States)

^c NONE

Author keywords

Effective intestinal permeability across rat jejunum (Peff); Intestinal absorption rate constant (ka); Net water flux (NWF); P glycoprotein (P gp); Saquinavir (SQV); Single pass intestinal perfusion (SPIP)

Indexed keywords

CYCLOSPORIN; DIPEPTIDE; GLYCINE; GLYCOPROTEIN P; GLYCYLSARCOSINE; PRODRUG; SAQUINAVIR; VALINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG STABILITY; DRUG TRANSPORT; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; LIVER HOMOGENATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG STABILITY; HIV PROTEASE INHIBITORS; INTESTINAL ABSORPTION; JEJUNUM; MALE; P-GLYCOPROTEIN; PERMEABILITY; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SAQUINAVIR;

EID: 34247567472     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.11.058     Document Type: Article

References (36)

1. Alsenz J., Steffen H., and Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. 15 (1998) 423-428
2. Anand B.S., Katragadda S., and Mitra A.K. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J. Pharmacol. Exp. Ther. 311 (2004) 659-667
3. Bachmeier C.J., Spitzenberger T.J., Elmquist W.F., and Miller D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22 (2005) 1259-1268
4. Balimane P.V., Tamai I., Guo A., Nakanishi T., Kitada H., Leibach F.H., Tsuji A., and Sinko P.J. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem. Biophys. Res. Commun. 250 (1998) 246-251
5. Berggren S., Hoogstraate J., Fagerholm U., and Lennernas H. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 21 (2004) 553-560
6. Bolger M.B., Haworth I.S., Yeung A.K., Ann D., von Grafenstein H., Hamm-Alvarez S., Okamoto C.T., Kim K.J., Basu S.K., Wu S., and Lee V.H. Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J. Pharm. Sci. 87 (1998) 1286-1291
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Cummins C.L., Salphati L., Reid M.J., and Benet L.Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305 (2003) 306-314
9. Dupre J., Behme M.T., Hramiak I.M., McFarlane P., Williamson M.P., Zabel P., and McDonald T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44 (1995) 626-630
10. Edwards J.E., Brouwer K.R., and McNamara P.J. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob. Agents Chemother. 46 (2002) 2284-2286
11. Fagerholm U., Johansson M., and Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13 (1996) 1336-1342
12. Fitzsimmons M.E., and Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25 (1997) 256-266
13. Germann U.A. P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A (1996) 927-944
14. Issa C., Gupta P., and Bansal A.K. Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. AAPS PharmSciTech 4 (2003) E16
15. Ito K., Kusuhara H., and Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16 (1999) 225-231
16. Jain R., Majumdar S., Nashed Y., Pal D., and Mitra A.K. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol. Pharm. 1 (2004) 290-299
17. Jain R., Agarwal S., Majumdar S., Zhu X., Pal D., and Mitra A.K. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303 (2005) 8-19
18. Kakuda T.N., Struble K.A., and Piscitelli S.C. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am. J. Health Syst. Pharm. 55 (1998) 233-254
19. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
20. Lee K.J., Mower R., Hollenbeck T., Castelo J., Johnson N., Gordon P., Sinko P.J., Holme K., and Lee Y.H. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm. Res. 20 (2003) 1015-1021
21. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., Brown M.B., Guo W., Rossi S.J., Benet L.Z., and Watkins P.B. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62 (1997) 248-260
22. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., and Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16 (1999) 1206-1212
23. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3 (2006) 3-25
24. Rice A., Michaelis M.L., Georg G., Liu Y., Turunen B., and Audus K.L. Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J. Mol. Neurosci. 20 (2003) 339-343
25. Rouquayrol M., Gaucher B., Roche D., Greiner J., and Vierling P. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. Pharm. Res. 19 (2002) 1704-1712
26. Rousselle C., Clair P., Lefauconnier J.M., Kaczorek M., Scherrmann J.M., and Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57 (2000) 679-686
27. Savolainen J., Edwards J.E., Morgan M.E., McNamara P.J., and Anderson B.D. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats. Drug Metab. Dispos. 30 (2002) 479-482
28. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., and Merigan T.C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124 (1996) 1039-1050
29. Sugawara M., Huang W., Fei Y.J., Leibach F.H., Ganapathy V., and Ganapathy M.E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89 (2000) 781-789
30. Tamai I., and Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89 (2000) 1371-1388
31. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7735-7738
32. Tsuji A., and Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13 (1996) 963-977
33. Ucpinar S.D., and Stavchansky S. Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High performance liquid chromatography. Biomed. Chromatogr. 17 (2003) 21-25
34. Varma M.V., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48 (2003) 347-359
35. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27 (1997) 161-170
36. Williams G.C., Liu A., Knipp G., and Sinko P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46 (2002) 3456-3462